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Coronary artery disease is a diffuse process, and patients 
presenting with ST-segment elevation myocardial infarction 
(STEMI) have multiple lesions that may be suitable for per-
cutaneous coronary intervention (PCI). The best strategy 
regarding PCI for STEMI in multivessel disease is an unre-
solved issue. Although current guidelines recommend that 
PCI in non-culprit arteries should not be attempted unless 
the patient is hemodynamically unstable,
1)2) it is uncertain 
whether PCI of the infarct-related artery only or a strategy of 
complete revascularization, either in a simultaneous or stag-
ed multivessel PCI approach, will improve outcome.
In contemporary medical therapy, it is not clear whether in-
tervening to treat stable chronic nonculprit lesions in patients 
with STEMI can prevent major adverse cardiovascular events. 
Moreover, multivessel stenting in this setting could poten-
tially be associated with greater contrast usage and peripro-
cedural myocardial infarction secondary to side branch clo-
sure and distal embolization.
3)
In this Korean Acute Myocardial Infarction Registry-Based 
Analysis (KAMIR)-based study,
4) we compared the clinical 
outcomes of multivessel revascularization vs. those of infarct-
related artery (IRA)-only revascularization in patients under-
going primary PCI for STEMI. Although this was a retrospec-
tive study, 1,094 STEMI patients were analyzed, and this is one 
of the largest data collections regarding STEMI patients in 
Korea. There were no significant differences between the 2 
groups in terms of death, myocardial infarction, or revascu-
larization. However, when the complete primary revascular-
ized patients were compared with the incomplete primary re-
vascularized patients, the non-target vessel revascularization 
rate was significantly higher in the incompletely revascular-
ized patients when compared with the completely revascular-
ized group (8.6 vs. 1.8%, p=0.002). This seems obvious consid-
ering the fact that other non-target vessels in the incomplete 
revascularized group could cause significant ischemia, thereby 
requiring subsequent procedures. However, complete prima-
ry revascularization itself has multiple risks which could be fa-
tal to the patients, such as acute stent thrombosis, side branch 
occlusion, and distal embolization. 
Based on available data, PCI of the culprit lesion has the ad-
vantages of shorter procedure duration, a smaller amount of 
dye used, and a lower rate of periprocedural myocardial in-
farctions, while complete revascularization has lower rates of 
recurrent angina and a better left ventricular ejection frac-
tion. Although available data provide controversial results 
concerning the right strategy to choose, a strategy of multi-
vessel PCI should be pursued considering the timing of 
complete revascularization. Patients with STEMI are in a 
heightened thrombotic and inflammatory state and may be 
more prone to the adverse effects of multivessel PCI.
5)6) Fur-
thermore, multivessel disease is associated with increased in-
stent restenosis, and placing of multiple stents may be asso-
ciated with increased revascularization secondary to in-stent 
restenosis.
7) The safety and efficacy of multivessel PCI was ex-
amined in a subpopulation of the Treat angina with Aggra-
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stat and determine Cost of Therapy with an Invasive or 
Conservative Strategy-Thrombolysis in Myocardial Infarc-
tion-18) trial. Of the 290 patients with multivessel disease, 
224 underwent culprit lesion and 66 underwent multivessel 
stenting.
8) There were no significant differences for the 
6-month composite end points of death or MI, which were 
similar to the KAMIR data.
8) After comparing all the risks 
and benefits of complete revascularization, staged complete 
revascularization should be the treatment of choice in pa-
tients with STEMI. 
The KAMIR study has several limitations. First, it was an 
observational study. Second, the attitude of the operator and 
the progression of the procedure are very important, but very 
difficult to measure in an observational study. Third, indi-
viduals who undergo multivessel PCI may receive more fol-
low-up procedures. These differences would most likely lead 
to more revascularization in patients with multivessel PCI. 
Finally, the KAMIR data did not include contrast volume and 
fluoroscopy time. 
In a large cohort of KAMIR patients with STEMI undergo-
ing PCI, nonculprit multivessel drug-eluting stenting was as-
sociated with a lower incidence of non-target vessel revascu-
larization, thereby reducing the rates of MACE in the com-
plete primary revascularization group. However, complete 
primary revascularization should be carefully considered in 
patients with hemodynamically stable STEMI, because mul-
tivessel drug-eluting stenting could potentially have adverse 
effects secondary to increased contrast load and side branch 
closure, leading to renal failure and periprocedural MI, resp-
ectively.
9) To avoid the potential risks of simultaneous multi-
vessel PCI, a strategy of staged complete revascularization 
appears to be the best choice. Current guidelines should be re-
evaluated to account for these considerations. Adequately po-
wered randomized controlled trials should be performed to 
endorse current knowledge.
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